The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $3.57 billion in 2025 to $4.98 billion in 2026 at a compound annual growth rate (CAGR) of 39.6%. The growth in the historic period can be attributed to rising prevalence of obesity, increasing incidence of type 2 diabetes, high consumption of processed foods, lack of awareness about liver health, limited treatment options for early-stage nash.
The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $18.97 billion in 2030 at a compound annual growth rate (CAGR) of 39.7%. The growth in the forecast period can be attributed to advancements in precision medicine, development of novel nash drugs, adoption of digital health monitoring tools, government initiatives for liver disease prevention, increasing investment in liver disease research. Major trends in the forecast period include personalized lifestyle & diet management, non-invasive diagnostic advancements, fatty liver disease awareness programs, home-based liver health monitoring, novel pharmacological agents development.
The increasing prevalence of insulin resistance has driven the growth of the non-alcoholic steatohepatitis (NASH) treatment market. Insulin resistance occurs when cells in muscles, fat, and the liver do not respond effectively to insulin, resulting in high blood sugar levels. It is commonly linked to an unhealthy lifestyle, excessive sugar intake, and genetic factors. The rise in insulin resistance has been associated with an increase in diabetes and other liver-related issues, conditions that are often treated with NASH therapies. For example, in July 2025, PubMed, a U.S.-based biomedical literature database, reported a significant increase in the prevalence of obesity, abdominal obesity, severe obesity, and insulin resistance, with rates rising from 34.9% to 41.4%, 62.5% to 67%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Consequently, the growing prevalence of insulin resistance due to liver and diabetes-related diseases is expected to propel the NASH treatment market.
Major companies in the non-alcoholic steatohepatitis (NASH) treatment market are focusing on innovative products like endogenous hormones to expand their customer bases, increase sales, and drive revenue growth. Endogenous hormones are naturally occurring substances in the body that regulate various physiological functions. For example, in September 2023, 89bio Inc., a U.S.-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin in individuals diagnosed with NASH. Pegozafermin is an engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). This innovative product is being developed for NASH and severe hypertriglyceridemia (SHTG). The use of glycoPEGylated technology in Pegozafermin gives it an extended half-life while preserving its potency, enhancing its ability to modulate key factors such as triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.
In September 2023, Kriya Therapeutics, a U.S.-based biotechnology company focused on gene therapy for metabolic and neurodegenerative diseases, acquired Tramontane Therapeutics for an undisclosed amount. This acquisition enhances Kriya's NASH treatment pipeline by adding a one-time gene therapy program targeting Fibroblast Growth Factor 21 (FGF21), further strengthening its capabilities in metabolic-liver disease therapeutics. Tramontane Therapeutics, a Spain-based biotechnology company, specializes in gene therapy programs for metabolic and neurodegenerative diseases, and its lead candidate for NASH utilizes AAV-mediated FGF21 expression.
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG.
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-alcoholic steatohepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the non-alcoholic steatohepatitis treatment market by affecting the cost and availability of imported active pharmaceutical ingredients (APIs) and advanced diagnostic equipment. This has increased production costs for drugs like pioglitazone and obeticholic acid, particularly impacting Asia-Pacific suppliers and distributors. Hospital pharmacies and specialty drug segments are most affected, while some domestic manufacturers benefit from protective tariffs by gaining a competitive advantage in local markets.
The non-alcoholic steatohepatitis treatment market research report is one of a series of new reports that provides non-alcoholic steatohepatitis treatment market statistics, including non-alcoholic steatohepatitis treatment industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis treatment market share, detailed non-alcoholic steatohepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis treatment industry. This non-alcoholic steatohepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-alcoholic steatohepatitis (NASH) treatment involves approaches such as maintaining a healthy diet, controlling blood sugar, and promoting weight and fat loss. NASH is a liver disease where individuals, who consume little or no alcohol, develop fatty livers, leading to liver cell damage and inflammation. If untreated, this can progress to cirrhosis.
The main drugs used in NASH treatment include vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, obeticholic acid, and others. Vitamin E is a fat-soluble nutrient that helps reduce oxidative stress in liver cells, reducing liver damage and inflammation, while pioglitazone works to improve insulin sensitivity and manage high blood sugar levels, often linked to type 2 diabetes. Diagnostic tests such as blood tests, liver biopsies, and imaging procedures are used to monitor the condition, with treatment distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies.
The non-alcoholic steatohepatitis treatment market includes revenues earned by entities by providing services such as liver related ?medical diagnosis and tests, fatty liver management and treatment, abdominal ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $18.97 billion in 2030 at a compound annual growth rate (CAGR) of 39.7%. The growth in the forecast period can be attributed to advancements in precision medicine, development of novel nash drugs, adoption of digital health monitoring tools, government initiatives for liver disease prevention, increasing investment in liver disease research. Major trends in the forecast period include personalized lifestyle & diet management, non-invasive diagnostic advancements, fatty liver disease awareness programs, home-based liver health monitoring, novel pharmacological agents development.
The increasing prevalence of insulin resistance has driven the growth of the non-alcoholic steatohepatitis (NASH) treatment market. Insulin resistance occurs when cells in muscles, fat, and the liver do not respond effectively to insulin, resulting in high blood sugar levels. It is commonly linked to an unhealthy lifestyle, excessive sugar intake, and genetic factors. The rise in insulin resistance has been associated with an increase in diabetes and other liver-related issues, conditions that are often treated with NASH therapies. For example, in July 2025, PubMed, a U.S.-based biomedical literature database, reported a significant increase in the prevalence of obesity, abdominal obesity, severe obesity, and insulin resistance, with rates rising from 34.9% to 41.4%, 62.5% to 67%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Consequently, the growing prevalence of insulin resistance due to liver and diabetes-related diseases is expected to propel the NASH treatment market.
Major companies in the non-alcoholic steatohepatitis (NASH) treatment market are focusing on innovative products like endogenous hormones to expand their customer bases, increase sales, and drive revenue growth. Endogenous hormones are naturally occurring substances in the body that regulate various physiological functions. For example, in September 2023, 89bio Inc., a U.S.-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin in individuals diagnosed with NASH. Pegozafermin is an engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). This innovative product is being developed for NASH and severe hypertriglyceridemia (SHTG). The use of glycoPEGylated technology in Pegozafermin gives it an extended half-life while preserving its potency, enhancing its ability to modulate key factors such as triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.
In September 2023, Kriya Therapeutics, a U.S.-based biotechnology company focused on gene therapy for metabolic and neurodegenerative diseases, acquired Tramontane Therapeutics for an undisclosed amount. This acquisition enhances Kriya's NASH treatment pipeline by adding a one-time gene therapy program targeting Fibroblast Growth Factor 21 (FGF21), further strengthening its capabilities in metabolic-liver disease therapeutics. Tramontane Therapeutics, a Spain-based biotechnology company, specializes in gene therapy programs for metabolic and neurodegenerative diseases, and its lead candidate for NASH utilizes AAV-mediated FGF21 expression.
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG.
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-alcoholic steatohepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the non-alcoholic steatohepatitis treatment market by affecting the cost and availability of imported active pharmaceutical ingredients (APIs) and advanced diagnostic equipment. This has increased production costs for drugs like pioglitazone and obeticholic acid, particularly impacting Asia-Pacific suppliers and distributors. Hospital pharmacies and specialty drug segments are most affected, while some domestic manufacturers benefit from protective tariffs by gaining a competitive advantage in local markets.
The non-alcoholic steatohepatitis treatment market research report is one of a series of new reports that provides non-alcoholic steatohepatitis treatment market statistics, including non-alcoholic steatohepatitis treatment industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis treatment market share, detailed non-alcoholic steatohepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis treatment industry. This non-alcoholic steatohepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-alcoholic steatohepatitis (NASH) treatment involves approaches such as maintaining a healthy diet, controlling blood sugar, and promoting weight and fat loss. NASH is a liver disease where individuals, who consume little or no alcohol, develop fatty livers, leading to liver cell damage and inflammation. If untreated, this can progress to cirrhosis.
The main drugs used in NASH treatment include vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, obeticholic acid, and others. Vitamin E is a fat-soluble nutrient that helps reduce oxidative stress in liver cells, reducing liver damage and inflammation, while pioglitazone works to improve insulin sensitivity and manage high blood sugar levels, often linked to type 2 diabetes. Diagnostic tests such as blood tests, liver biopsies, and imaging procedures are used to monitor the condition, with treatment distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies.
The non-alcoholic steatohepatitis treatment market includes revenues earned by entities by providing services such as liver related ?medical diagnosis and tests, fatty liver management and treatment, abdominal ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Non-Alcoholic Steatohepatitis Treatment Market Characteristics
3. Non-Alcoholic Steatohepatitis Treatment Market Supply Chain Analysis
4. Global Non-Alcoholic Steatohepatitis Treatment Market Trends and Strategies
5. Non-Alcoholic Steatohepatitis Treatment Market Analysis of End Use Industries
7. Global Non-Alcoholic Steatohepatitis Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Non-Alcoholic Steatohepatitis Treatment Total Addressable Market (TAM) Analysis for the Market
9. Non-Alcoholic Steatohepatitis Treatment Market Segmentation
10. Non-Alcoholic Steatohepatitis Treatment Market Regional and Country Analysis
11. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market
12. China Non-Alcoholic Steatohepatitis Treatment Market
13. India Non-Alcoholic Steatohepatitis Treatment Market
14. Japan Non-Alcoholic Steatohepatitis Treatment Market
15. Australia Non-Alcoholic Steatohepatitis Treatment Market
16. Indonesia Non-Alcoholic Steatohepatitis Treatment Market
17. South Korea Non-Alcoholic Steatohepatitis Treatment Market
18. Taiwan Non-Alcoholic Steatohepatitis Treatment Market
19. South East Asia Non-Alcoholic Steatohepatitis Treatment Market
20. Western Europe Non-Alcoholic Steatohepatitis Treatment Market
21. UK Non-Alcoholic Steatohepatitis Treatment Market
22. Germany Non-Alcoholic Steatohepatitis Treatment Market
23. France Non-Alcoholic Steatohepatitis Treatment Market
24. Italy Non-Alcoholic Steatohepatitis Treatment Market
25. Spain Non-Alcoholic Steatohepatitis Treatment Market
26. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market
27. Russia Non-Alcoholic Steatohepatitis Treatment Market
28. North America Non-Alcoholic Steatohepatitis Treatment Market
29. USA Non-Alcoholic Steatohepatitis Treatment Market
30. Canada Non-Alcoholic Steatohepatitis Treatment Market
31. South America Non-Alcoholic Steatohepatitis Treatment Market
32. Brazil Non-Alcoholic Steatohepatitis Treatment Market
33. Middle East Non-Alcoholic Steatohepatitis Treatment Market
34. Africa Non-Alcoholic Steatohepatitis Treatment Market
36. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape and Company Profiles
37. Non-Alcoholic Steatohepatitis Treatment Market Other Major and Innovative Companies
40. Non-Alcoholic Steatohepatitis Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Non-Alcoholic Steatohepatitis Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses non-alcoholic steatohepatitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for non-alcoholic steatohepatitis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-alcoholic steatohepatitis treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Type: Vitamin E And Pioglitazone; Ocaliva; Elafibranor; Selonsertib And cenicriviroc; Obeticholic Acid; Other Drugs Types2) By Test Type: Blood Tests; Liver Biopsy; Imaging Procedures
3) By End User: Hospital Pharmacies; Retail And Specialty Pharmacies; Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements; Pioglitazone-Based Formulations.2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor Monotherapy; Elafibranor Combination Therapy
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations; Cenicriviroc Formulations
5) By Obeticholic Acid: Immediate-Release Obeticholic Acid; Extended-Release Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials; Combination Therapies
Companies Mentioned: AstraZeneca PLC; Galmed Pharmaceuticals Ltd.; Genfit S.A.; Zydus Cadila Healthcare Limited; Bristol-Myers Squibb Company; Gilead Sciences Inc.; Novo Nordisk A/S; Inventiva Pharma SA; NGM Biopharmaceuticals Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Corporation; Intercept Pharmaceuticals Inc.; Cirius Therapeutics Inc.; Viking Therapeutics Inc.; Eli Lilly and Company; Terns Pharmaceuticals Inc.; AbbVie Inc.; Johnson & Johnson Private Limited; Sanofi S.A.; F. Hoffmann-La Roche Ltd.; C.H. Boehringer Sohn AG & Co. KG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Non-Alcoholic Steatohepatitis Treatment market report include:- AstraZeneca PLC
- Galmed Pharmaceuticals Ltd.
- Genfit S.A.
- Zydus Cadila Healthcare Limited
- Bristol-Myers Squibb Company
- Gilead Sciences Inc.
- Novo Nordisk A/S
- Inventiva Pharma SA
- NGM Biopharmaceuticals Inc.
- Galectin Therapeutics Inc.
- Madrigal Pharmaceuticals Corporation
- Intercept Pharmaceuticals Inc.
- Cirius Therapeutics Inc.
- Viking Therapeutics Inc.
- Eli Lilly and Company
- Terns Pharmaceuticals Inc.
- AbbVie Inc.
- Johnson & Johnson Private Limited
- Sanofi S.A.
- F. Hoffmann-La Roche Ltd.
- C.H. Boehringer Sohn AG & Co. KG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.98 Billion |
| Forecasted Market Value ( USD | $ 18.97 Billion |
| Compound Annual Growth Rate | 39.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
